Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.

Abstract

BACKGROUND AND AIMS:

Both inflammation and fibrosis may be detected in Crohn's disease (CD). The molecular pattern of Basic Fibroblastic Growth Factor (bFGF) and Syndecan-1 (SD1) expression is altered in stenosing CD, but we do not know what the behaviour of this teamwork factor is in CD in deep remission under treatment with anti-TNFα antibodies. Our aim was to compare the expression of bFGF, SD1 and TNF-α in patients with CD in deep remission under treatment with Infliximab (IFX) or Adalimumab (ADA) and a control group of patients with active CD.

METHODS:

We assessed the expression of bFGF, SD1 and TNF-α in 10 patients with active CD and in 28 patients with CD in sustained deep remission for at least 6 months. All patients underwent surveillance colonoscopy with biopsies, while receiving maintenance therapy with IFX or ADA. Analysis was conducted by real-time reverse transcriptase PCR (RT-PCR) in biopsy samples.

RESULTS:

We found that bFGF, SD1 and TNF-α were significantly reduced under treatment with anti-TNFα versus controls (p=0.000). bFGF and SD1 expression were similar between IFX and ADA patients (p=0.335 and p=0.289, respectively), while TNF-α was significantly under-expressed in ADA patients (p=0.008).

CONCLUSIONS:

bFGF, SD1 and TNF-α are significantly reduced in CD patients in deep remission under treatment with anti-TNFα, likely as an expression of optimal control of inflammation. The significance of the TNF-α under-expression in patients under treatment with ADA with respect to those under treatment with IFX should be elucidated in further studies.

• Authors: Antonio Tursi, Walter Elisei, Mariabeatrice Principi, Cosimo Damiano Inchingolo, Rosanna Nenna, Marcello Picchio, Floriana Giorgio, Enzo Ierardi, Giovanni Brandimarte
• Journal: Journal of gastrointestinal and liver diseases : JGLD (J Gastrointestin Liver Dis) Vol. 23 Issue 3 Pg. 261-5 (Sep 2014) ISSN: 1842-1121 [Electronic] Romania
• PMID: 25267953 (Publication Type: Journal Article, Multicenter Study, Observational Study)

Chemical References

• Anti-Inflammatory Agents
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Gastrointestinal Agents
• SDC1 protein, human
• Syndecan-1
• Tumor Necrosis Factor-alpha
• Fibroblast Growth Factor 2
• Infliximab
• Adalimumab

Topics

• Adalimumab
• Adult
• Anti-Inflammatory Agents (therapeutic use)
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Biopsy
• Colon (drug effects, immunology, metabolism, pathology)
• Colonoscopy
• Crohn Disease (diagnosis, drug therapy, immunology, metabolism)
• Female
• Fibroblast Growth Factor 2 (metabolism)
• Gastrointestinal Agents (therapeutic use)
• Humans
• Infliximab
• Intestinal Mucosa (drug effects, immunology, metabolism, pathology)
• Italy
• Male
• Middle Aged
• Remission Induction
• Retrospective Studies
• Syndecan-1 (metabolism)
• Time Factors
• Treatment Outcome
• Tumor Necrosis Factor-alpha (antagonists & inhibitors, metabolism)
• Young Adult